SBIR/STTR Research Award
IGF OT IGF SBIR PHASE II TOPIC DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS
Award amount
$1,499,999Program and phase
SBIR · Phase IIAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LP Therapeutics Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- WJ5LCL2KWS81
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
The goal of this project is to develop nanometer scale micelles to deliver high concentration of the chemotherapeutic drug daunorubicin DNR directly into acute myeloid leukemia AML stem cells LSCs and eradicate AML from the very root LSCs are a special group of leukemia cells that are relatively resistant to conventional doses of chemotherapy can regenerate more leukemia cells and cause leukemia recurrence
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
2 SBIR/STTR records share this UEI (2014–2016). Reported award amounts total $1,724,362. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services